
    
      This is a double-blinded, Phase II trial in which 58 ambulatory IPF patients at any of four
      medical centers (University of Pittsburgh, University of Chicago, Geisinger Medical Center,
      and Temple University) will be randomized equally to 1. placebo or 2. two doses of rituximab
      1 gm i.v., with a 14 day interval inbetween doses.

      Subjects will be followed for 9 months.
    
  